Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial
- 1 April 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet Diabetes & Endocrinology
- Vol. 8 (4), 301-312
- https://doi.org/10.1016/s2213-8587(20)30026-7
Abstract
No abstract availableKeywords
Funding Information
- Seventh Framework Programme (279277, FP7/20072-013)
This publication has 30 references indexed in Scilit:
- Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathyNephrology Dialysis Transplantation, 2014
- CKD273, a New Proteomics Classifier Assessing CKD and Its PrognosisPLOS ONE, 2013
- Urinary Proteomics for Early Diagnosis in Diabetic NephropathyDiabetes, 2012
- Technical aspects and inter-laboratory variability in native peptide profiling: The CE–MS experienceClinical Biochemistry, 2012
- Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 DiabetesThe New England Journal of Medicine, 2011
- Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney DiseaseMolecular & Cellular Proteomics, 2010
- Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic NephropathyJournal of the American Society of Nephrology, 2009
- Effect of Candesartan on Microalbuminuria and Albumin Excretion Rate in DiabetesAnnals of Internal Medicine, 2009
- Beneficial impact of spironolactone in diabetic nephropathyKidney International, 2005
- The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 DiabetesThe New England Journal of Medicine, 2001